MedTrace Logo

DZD9008 PK Study in Hepatic Impairment Subjects

NCT06084104 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-12-18

No results posted yet for this study

Summary

This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function

Conditions

  • Hepatic Impairment

Interventions

DRUG

DZD9008

A single oral dose of 200mg DZD9008

DRUG

DZD9008

A single oral dose of 200mg DZD9008

Sponsors & Collaborators

  • PPD Development, L.P.

    collaborator UNKNOWN

  • Dizal Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Thomas C Marbury, MD · Orlando Clinical Research Center

  • Eric Lawitz, MD · Texas Liver Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-17
Primary Completion
2024-06-12
Completion
2024-10-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06084104 on ClinicalTrials.gov